BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Single Dose Escalation Study in Patients With Chronic Heart Failure

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: BAY60-4552

First Posted Date: 2007-11-30

Last Posted Date: 2016-08-10

Lead Sponsor: Bayer

Target Recruit Count: 55

Registration Number: NCT00565565

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)

First Posted Date: 2007-11-26

Last Posted Date: 2013-11-26

Lead Sponsor: Bayer

Target Recruit Count: 21

Registration Number: NCT00562913

Sorafenib/Docetaxel Dose Escalation Trial

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2007-11-22

Last Posted Date: 2013-05-23

Lead Sponsor: Bayer

Target Recruit Count: 17

Registration Number: NCT00562523

A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis

Phase 4

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Azelastine and placebo
Drug: Cetirizine and Placebo
Drug: Loratadine and Placebo
Drug: Placebo and Placebo (spray and Tablet)

First Posted Date: 2007-11-21

Last Posted Date: 2013-05-07

Lead Sponsor: Bayer

Target Recruit Count: 70

Registration Number: NCT00561717

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

Phase 2

Terminated

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Cinaciguat (BAY58-2667)

First Posted Date: 2007-11-16

Last Posted Date: 2017-04-18

Lead Sponsor: Bayer

Target Recruit Count: 150

Registration Number: NCT00559650

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sorafenib + Paclitaxel + Carboplatin
Drug: Placebo + Paclitaxel + Carboplatin

First Posted Date: 2007-11-15

Last Posted Date: 2013-12-27

Lead Sponsor: Bayer

Target Recruit Count: 91

Registration Number: NCT00558636

ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Lonaprisan (ZK 230211, BAY86-5044)

First Posted Date: 2007-11-09

Last Posted Date: 2014-10-10

Lead Sponsor: Bayer

Target Recruit Count: 68

Registration Number: NCT00555919

BENEFIT Extension Study

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2007-10-16

Last Posted Date: 2012-03-05

Lead Sponsor: Bayer

Target Recruit Count: 283

Registration Number: NCT00544037

ZK283197 for Treatment of Vasomotor Symptoms

Phase 2

Completed

Conditions: Vasomotor System

Interventions: Drug: BAY 86-5310 (ZK 283197)
Drug: Placebo
Drug: 17ß-estradiol

First Posted Date: 2007-10-01

Last Posted Date: 2015-04-09

Lead Sponsor: Bayer

Target Recruit Count: 116

Registration Number: NCT00537836

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: LCS12
Drug: LCS16

First Posted Date: 2007-09-12

Last Posted Date: 2017-01-25

Lead Sponsor: Bayer

Target Recruit Count: 2885

Registration Number: NCT00528112

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy